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NEOPLASIA
Selection and characterization of BCR-ABL positive cell lines
with differential sensitivity to the tyrosine kinase inhibitor
STI571: diverse mechanisms of resistance
Franc ¸ois Xavier Mahon, Michael W. N. Deininger, Beate Schultheis, Je ´rome Chabrol, Josy Reiffers,
John M. Goldman, and Junia V. Melo
Targeting the tyrosine kinase activity of
Bcr-Abl with STI571 is an attractive thera-
peutic strategy in chronic myelogenous
leukemia (CML). A few CML cell lines and
primary progenitors are, however, resis-
tant to this compound. We investigated
the mechanism of this resistance in
clones of the murine BaF/3 cells trans-
fected with BCR-ABL and in 4 human cell
lines from which sensitive (s) and resis-
tant (r) clones were generated by various
methods. Although the resistant cells
were able to survive in the presence of
STI571, their proliferation was approxi-
mately 30% lower than that of their
sensitive counterparts in the absence of
the compound. The concentration of
STI571 needed for a 50% reduction in
viable cells after a 3-day exposure was on
average 10 times higher in the resistant
(2-3 mmol/L) than in the sensitive (0.2-0.25
mmol/L) clones. The mechanism of resis-
tance to STI571 varied among the cell
lines. Thus, in Baf/BCR-ABL-r, LAMA84-r,
and AR230-r, there was up-regulation of
theBcr-Ablproteinassociatedwithampli-
ﬁcation of the BCR-ABL gene. In K562-r,
there was no Bcr-Abl overexpression, but
the IC50 for the inhibition of Bcr-Abl
autophosphorylation was increased in
the resistant clones. Sequencing of the
Abl kinase domain revealed no muta-
tions. The multidrug resistance P-glyco-
protein (Pgp) was overexpressed in
LAMA84-r, indicating that at least 2
mechanisms of resistance operate in this
cell line. KCL22-r showed neither Bcr-Abl
up-regulation nor a higher threshold for
tyrosine kinase inhibition by STI571. We
conclude that BCR-ABL–positive cells
can evade the inhibitory effect of STI571
by different mechanisms, such as Bcr-Abl
overexpression, reduced intake mediated
by Pgp, and, possibly, acquisition of
compensatory mutations in genes other
than BCR-ABL. (Blood. 2000;96:1070-1079)
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Introduction
The t(9;22)(q34;q11) reciprocal chromosomal translocation occurs
in nearly all patients with chronic myelogenous leukemia (CML)
and in approximately 25% of adults and 5% of children with acute
lymphoblastic leukemia (ALL).1 This translocation gives origin to
a 22q2, or Philadelphia (Ph), chromosome that contains a BCR-
ABL hybrid gene, the molecular hallmark of CML and of Ph-
positive ALL.2 BCR-ABL encodes an oncogenic fusion protein of
190, 210, or 230 kd, depending on the breakpoint on the BCR gene
(reviewed in 1). The unifying feature of all these Bcr-Abl fusion
proteins is their deregulated protein tyrosine kinase activity. The
latter is responsible for the in vitro transformation effect and the in
vivo leukemogenic property of Bcr-Abl.3,4 Targeting the tyrosine
kinase activity of Bcr-Abl is, therefore, an attractive therapeutic
strategy in CML or in BCR-ABL–positive ALL. Toward this aim,
several inhibitors of tyrosine kinase were recently developed.5,6
Amongthesemolecules,STI571,previouslyknownasCGP57148B,
a 2-phenylaminopyrimidine derivative, is among the most promis-
ing and selective inhibitors of Bcr-Abl tyrosine kinase activity. It
inhibits competitively the binding of adenosine triphosphate (ATP)
to the kinase domain of Abl at micromolar concentrations. Most
other serine/threonine and tyrosine kinases are unaffected, but there
is a suppressive effect against the Kit and PDGF receptor kinase
activities.7,8
We and others8,9 have reported that STI571 speciﬁcally abro-
gates CML granulocyte macrophage–colony-forming unit (GM-
CFU) and erythroid burst-forming unit (BFU-e) colony formation
over a 2-log dose range, with a maximum differential effect
at 1 µmol/L. The inhibitor also suppresses proliferation of most
Ph-positive cell lines.9,10 Nevertheless, a few BCR-ABL–positive
GM-CFU colonies from peripheral blood or bone marrow
survive in the presence of the compound, and 2 of 10 Ph-positive
cell lines were found to be resistant to STI571.9 The reasons for
this reduced sensitivity to STI571 in some cells is unknown, but it
is an issue of considerable relevance as this compound enters
clinical trials.11
In this study, we have generated resistant and sensitive sublines
from different Ph-positive cell lines to investigate the mechanism
of resistance to STI571. We show that the Bcr-Abl protein is
signiﬁcantly overexpressed in some, but not all, resistant cell lines.
Similarly, the multidrug resistance P-glycoprotein (Pgp) is
overexpressed in 1 of the resistant cell lines. Overall, our
data suggest that BCR-ABL–positive cells can evade the
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Materials and methods
Cell lines
BaF/3 cells were grown in RPMI 1640 medium (Gibco, Paisley, UK)
supplemented with penicillin, streptomycin, L-glutamine, and 10% fetal
bovine serum (FBS), herein referred to as RF-10, with 10% WEHI-
conditioned medium as a source of murine IL-3. The Baf/BCR-ABL line
was obtained by standard electroporation transfection with the wild-type
(wt) BCR-ABL–containing pGD210 expression vector12 (kindly provided
by Dr George Daley, Whitehead Institute, Cambridge, MA), as described.13
Nine BCR-ABL–positive human cell lines were used in this study:
K562, KYO1, LAMA84, EM2, EM3, BV173,AR230, KU812, and KCL22.
They were all grown in RF-10. These cell lines were purchased from cell
repository banks (American Tissue Culture Collection, Rockville, MD;
European Collection of Cell Cultures, Winchester, UK; German Collection
of Micro-organisms and Cell Cultures, Braunschweig, Germany) or were
kindly donated by the originators.
Generation of resistant cell lines by cloning in methylcellulose
Exponentially growing cells from each cell line were plated at 0.5 3 103 to
1 3 104 cells/mL in Iscove methylcellulose medium (Methocult H4430;
Stemcell Technologies, Vancouver, BC, Canada) supplemented with 10%
fetal bovine serum. STI571 (kindly provided by Dr Elisabeth Buchdunger,
Novartis, Basel, Switzerland) was added directly to the methylcellulose at
different concentrations (0.5-10 µmol/L) from a 10-mmol/L stock solution
in distilled water. Colonies were checked and selected for isolation at
different days of the culture, depending on the cell line (day 5, 7, 10, or 12).
Individual and well-separated colonies were plucked with a micropipette
ﬁtted with a sterile plugged tip, transferred to liquid culture, and expanded
in RF-10 in the same concentration of STI571 used in semisolid culture.
Generation of resistant cell lines in liquid culture
Cell lines maintained in liquid culture, as described above, were gradually
exposed to increasing concentrations of STI571 at a rate of 0.1-µmol/L
increment every 10 days of culture.After approximately 3 months, sublines
of cells growing in 1 µmol/L STI571 were maintained continuously in
culture in this dose of the inhibitor. Parental, sensitive cell lines were
maintained in parallel cultures without STI571 to be used as controls.
Cell proliferation assay
Cell proliferation assay was performed using MTS tetrazolium (Cell
Titer96 Aqueous; Promega, Madison, WI), which measures numbers of
viable cells. Between 2 3 103 and 2 3 104 cells were washed twice in
RF-10 and plated in quadruplicate into microtiter-plate wells in 100 µL
RF-10 plus various doses of STI571. Controls using the same concentra-
tions of STI571 without cells were set up in parallel. Twenty microliters
MTS was added to the wells at daily intervals. Two hours after MTS was
added, the plates were read in a microplate autoreader (Dynex Technolo-
gies, Billingshurst, UK) at 490-nm wavelength. Results are expressed as the
mean optical density of the 4-well set for each STI571 dose. All
experiments were repeated at least 3 times.
Cell viability assay
Cells were plated at a density of 2 to 2.5 3 105 cells/mL in RF-10 with or
without the inhibitor and, in some experiments, with or without 5 µg/mL
verapamil (Isoptine; Laboratoires Knoll, Levallois–Perret, France). Ali-
quots were taken out at 24-hour intervals for assessment of cell viability by
trypan blue exclusion.
Apoptosis assay
For determination of apoptotic death, the level of caspase-3 activation was
assessed by measurement of its capacity to cleave an Ac-Asp-Glu-Val-Asp-
amino-4-methyl-coumarine (Ac-DEVD) substrate, as modiﬁed from a
previously published method.14Aliquots of 7.5 3 104 cells were cultured in
triplicate in RF-10 into 96-well plates in the presence or absence of 1
µmol/L STI571. Triplicate wells with RF-10 only were used as background
control. After 3 days the plate was centrifuged at 1500 rpm for 5 minutes,
the culture supernatant was removed, and the cells were resuspended in 50
µL of a buffer containing 10 mmol/L HEPES, 5 mmol/L dithiothreitol, 2
mmol/L EDTA, 0.02% saponin, 1 mmol/L phenylmethylsulfonyl ﬂuoride,
10 µg/mL pepstatin A, 10 µg/mL leupeptin, and 72 mmol/L ﬂuorogenic
Ac-DEVDsubstrate(UBIEuromedex,Souffelweyerssheim,France).Devel-
opment of the reaction was read on an automatic spectroﬂuorometer (Victor
2 Multilabel Counter; Wallac and Perkin Elmer, Akron, OH), using lexc 5
380 nm and lem 5 480 nm. After this reading, 200 µL of a 15 mg/mL
propidium iodide solution was added to each well, and a new reading was
taken at lexc 5 360 nm and lem 5 600 nm to evaluate the proliferation of
cells. The caspase-3 activity was calculated for 105 cells after taking into
account the degree of cell proliferation.
Western blot analysis
Protein lysates were prepared according to the method of Kabarowski et
al.15 Protein concentrations were determined by the Bradford method (Dc
Protein Assay; BIO-RAD, Hercules, CA). Approximately 250 µg protein
was resolved on 7% SDS-PAGE gels, blotted onto polyvinylidene diﬂuo-
ride membranes (Immobilon-P; Millipore, Bedford, MA) by semi-dry
electrophoretic transfer, probed with individual antibodies, and visualized
by the ECL system (Amersham, Little Chalfont, UK). The following
antibodies were used: PY-99 anti-phosphotyrosine (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), anti-AblAb-3 (Calbiochem–Novabiochem, Notting-
ham, UK), A-2066 anti-actin (Sigma Chemical, St. Louis, MO), and
anti-Bcr (BCR 157; kind gift from R. Arlinghaus, MD Anderson Cancer
Center, Houston, TX). Secondary antibodies were horseradish peroxidase-
conjugated rabbit antimouse IgG and swine antirabbit IgG (DAKO,
Glostrup, Denmark).
Northern blot analysis
RNA was extracted by the acid guanidinium thiocyanate method.16 Fifteen
micrograms per lane were resolved on a 0.8% agarose gel and transferred
ontonylonmembranes(HYBOND;Amersham).Theﬁlterswereprehybrid-
ized, hybridized, and washed according to the manufacturer’s instructions.
ABL and BCR cDNA probes were prepared by reverse transcription–
polymerase chain reaction (RT-PCR) ampliﬁcation with primers A21,5 8
TTCAGCGGCCAGTAGCATCTGACTT, and A4e2,5 8) CTTCAAG-
GTCTTCACGGCCACCGT,forABLandBCRB1,58CCCCCGGAGTTTT-
GAGGATTGC, and BE22,5 8 AGGTAGATCTCCTCGCTAGCCAG-
GATT, for BCR. The probes were labeled with the Megaprime system
(Amersham).After posthybridization washes, the membranes were exposed
to autoradiography ﬁlm for 12 to 48 hours.
Southern blot analysis
Genomic DNA was isolated using the QIAmp Tissue Kit (QIAGEN,
Crawley, UK) digested with appropriate restriction enzymes, electropho-
resed on 0.8% agarose gels, and transferred to a nylon membrane
(HYBOND; Amersham). Southern hybridizations were carried out accord-
ing to protocols standardized by the manufacturers for this membrane. ABL
and BCR cDNA probes prepared as described for the Northern blots were
labeled with the Megaprime system (Amersham).
Sequence of the ABL kinase domain
The kinase domain of ABL was ampliﬁed by RT-PCR with primers NTPB1,
58 AAGCGCAACAAGCCCACTGTCTAT, and NTPE2,5 8 CTTCGTCT-
GAGATACTGGATTCCT. PCR products were cloned into the pCR2.1 TA
cloning vector (Invitrogen, Groningen, The Netherlands) and sequenced
with M13 primers on an ABI prism 377 automated DNA sequencer (PE
Applied Biosystems; Perkin Elmer, Cheshire, UK). Sequence analysis was
performed using the GCG version 10 software (Griffith University,
Brisbane,Australia).
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A phycoerythrin-conjugated monoclonal antibody (mAb) Fab’ fragment of
a murine anti-human Pgp (clone UIC2; Immunotech, Marseille, France)
was used to determine the expression of the MDR-1 gene product on the
different cell lines. HL-60 cells stably transfected with MDR-1 (a kind gift
from Dr S. Devereux, University College Hospital, London, UK) was used
as a positive control for Pgp expression. For detection of the Bcr-Abl
protein, cells were ﬁxed in 1% paraformaldehyde/phosphate-buffered saline
for 10 minutes at room temperature, permeabilized with 0.3% saponin, and
stained with an anti-Abl antibody (24-11; Santa Cruz Biotechnology) and
then by ﬂuorescein isothiocyanate-conjugated goat antimouse IgG (Becton
Dickinson, San Jose, CA) as the secondary reagent. Appropriate isotypic
controls were used in all experiments. Stained cells were analyzed on a
FACScan with the aid of the Cell Quest software (Becton Dickinson).
Fluorescence in situ hybridization analysis
Interphase nuclei were hybridized with ﬂuorescently labeled probes for
ABLand BCR (Vysis, Downers Grove, IL) as previously described.9
Results
Generation of cell lines with differential sensitivity to STI571
Plating of Baf/BCR-ABL cells in methylcellulose containing differ-
ent doses of STI571 resulted in an 85% to 99% reduction in
clonogenicity, as compared to that of cells seeded in the absence of
STI571. Nine clones resistant to 1 to 4 µmol/L STI571 were
selected after initial passaging into liquid culture and were
expanded thereafter in RF-10 supplemented with STI571. Sensitive
Baf/BCR-ABL clones were obtained from colonies growing in the
absence of the inhibitor. Resistance was deﬁned by the capacity to
survive indeﬁnitely in the continuous presence of a given concen-
tration of STI571, as illustrated on Figure 1A for 1 of the 4
Baf/BCR-ABL-r clones resistant to 1 µmol/L of the compound.
Similar results were obtained for cells resistant to 2, 3, and 4
µmol/L (2, 2, and 1 clone, respectively). In this study we focused
mainly on the BaF/BCR-ABL cells resistant to 1 µmol/L. Whereas
proliferation of the parental Ba/F3 cells was totally unaffected by
STI571 concentrations up to at least 10 µmol/L, growth of the
Baf/BCR-ABL-s cell line was, as expected, profoundly inhibited
by as little as 1 µmol/L of the compound (Figure 1B). Baf/BCR-
ABL-r clones survived and proliferated at the speciﬁc dose used for
cloning but remained sensitive to higher concentrations of STI571
(Figure 1B).
Several attempts to generate STI571-resistant clones from the
human cell lines AR230, BV173, EM2, EM3, K562, KYO1,
KU812, and LAMA84 by direct plating in STI571-treated methyl-
cellulose failed.An alternative strategy was then devised by which
each line was seeded into 0.1 µmol/L STI571 in liquid culture and
exposed to 0.1-µmol/L increments in the concentration of the drug
every 10 days. No cells from BV173, EM2, KYO1, or KU812
survived doses larger than 0.2 to 0.3 µmol/L. In contrast, subpopu-
lations of cells from AR230, LAMA84, and K562 were able to
survive and grow in the presence of 1 µmol/L STI571 after 3
months of the initiation of this culture system. The threshold for
EM3 cells was lower, with 1 clone resistant to 0.5 µmol/L and 1 to
0.8 µmol/L STI571 being derived; this cell line was, therefore, not
included in the remaining studies. KCL22, a line that was initially
found to be resistant to STI571, was subcloned in methylcellulose,
and 25 colonies were then expanded in liquid culture.Among these,
2 clones each of cells sensitive and resistant to 1 µmol/L STI571
were selected for further analysis. As for the murine Baf/BCR-
ABL-r clones, resistance in the human lines was deﬁned as the
capacity to survive in the continuous presence of 1 µmol/L STI571
(Figure 2A). Attempts to increase the dose of STI571 above this
threshold were unsuccessful.
By means of a caspase-3 activation assay, we conﬁrmed that the
Figure 1. Growth characteristics of BCR-ABL–transformed Baf/3 cells resistant
to STI571. (A) Cell viability assessed by trypan blue exclusion of Baf/BCR-ABL cells
(r) and Baf/BCR-ABL cloned in 1 µmol/L STI571 (Baf/BCR-ABL-r1) (j), treated (n)
or not treated (X) with 1 µmol/L STI571. (B) Cell proliferation of Baf/3 cells,
Baf/BCR-ABL-s, and Baf/BCR-ABL-r1 under the effect of various concentrations of
STI571, as assessed by MTS uptake. Results are expressed as the mean OD490 of
quadruplicate cultures, which is directly proportional to the number of viable cells.
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as previously reported.9 Figure 2B illustrates the reduction in
apoptotic death in LAMA84-r, AR230-r, and K562-r, compared
with their parental sensitive lines, when treated with 1 µmol/L of
the inhibitor for 3 days.
To compare the growth kinetics of the various cell lines, MTS
cell proliferation assays were performed on cells exposed to 0.1,
0.5, 1, 5, and 10 µmol/L STI571 (Figure 3). Because we showed
that the growth inhibition induced by STI571 in most BCR-ABL–
positive cell lines occurred within 48 to 72 hours,9 we evaluated at
day 3 the dose of STI571 necessary to induce a 50% decrease in the
uptake of MTS (IP50), as measured by the optical density index.
Thus, the IP50 for LAMA84-s, AR230-s, and K562-s was, respec-
tively, 0.2, 0.25, and 0.2 µmol/L, in contrast to 2, 3, and 3 µmol/L
for their resistant counterparts. This indicated that the concentra-
tion of STI571 needed for a 50% reduction in the number of viable
cells after 3-day exposure to the compound was on average 10
times higher in the resistant cells than in the sensitive cells
(Figure 3). Nevertheless, although the resistant clones survived and
proliferated at 1 µmol/L STI571, their rate of proliferation was
approximately 30% lower than that of their sensitive counterparts
in the absence of the compound, and, as found for Baf/BCR-ABL-r
cells, they remained sensitive to the higher doses of STI571. For
KCL22 cells, signiﬁcant differences in growth inhibition between
the sensitive and the resistant clones were observed only after 5
days of culture in the various concentrations of STI571 (Figure 3).
This was because the sensitive KCL22 clones required more than 8
days of exposure to STI571 for a reduction to less than 10%
viability, in contrast to the other sensitive lines in which this effect
was achieved in 3 to 5 days of STI571-treated cultures (Figure 2A).
Some resistant cell lines overexpress Bcr-Abl
The level of Bcr-Abl protein in the different cell lines was studied
by immunoblotting with an anti-Abl antibody. All Baf/BCR-ABL-r
clones showed signiﬁcantly high levels of Bcr-Abl, compared with
the sensitive parental line, and the level of overexpression in-
creased with the degree of resistance (Figure 4A). Thus, clones
resistant to 1 µmol/L STI571 (lanes 2-5) expressed 5 to 9 times
more Bcr-Abl than Baf/BCR-ABL-s (lane 1), whereas those resis-
tant to 3 µmol/L STI571 showed a 34-fold overexpression of the
oncoprotein. These values were calculated by taking into account
the densitometry of the P210BCR-ABL band only, and they may,
therefore, be an underestimation of the overall Bcr-Abl production
because several reactive bands of multiple sizes, suggestive of
Bcr-Abl degradation fragments, were also detected in the resistant
cells (Figure 4B). The higher BCR-ABL expression in Baf/BCR-
ABL-r cells was also observed at the mRNAlevel by Northern blot
analysis (data not shown).
We next examined whether IL3 or STI571 could modify the
level of Bcr-Abl protein in the resistant clones (Figure 4B).
Removal of STI571 from the culture for 3 days led to a slight
reduction in the level of Bcr-Abl protein, an effect that was
enhanced by the addition of IL-3 (see p210/actin ratios). A
reduction in BCR-ABL expression was also observed at the
transcriptional level, estimated as 1.3-fold after 3 days and 11-fold
after 7 days of STI571 withdrawal (Figure 4C). These data indicate
that Bcr-Abl expression can be modulated by the tyrosine kinase
inhibitor itself in Baf/BCR-ABL-r cells and that the addition of
IL-3, combined with STI571 withdrawal, completely abrogated the
reactive Bcr-Abl overexpression of these clones.
Screening of the human cell lines yielded similar ﬁndings in
some cases. Northern blot hybridization with ABL and BCR cDNA
probes revealed a 1.6- and a 5.5-fold increase in BCR-ABL mRNA
expression in AR230-r and LAMA84-r, respectively, compared
with their sensitive counterparts (Figure 5A). This overexpression
was translated into protein overproduction as shown by a 6- and a
Figure 2. Growth characteristics of the human CML cell lines resistant to
STI571. (A) Cell viability assessed by trypan blue exclusion of LAMA84, AR230,
K562, and KCL22 sensitive (s) and resistant (r) clones cultured in the presence (1)o r
absence of 1 µmol/LSTI571. (B) Caspase 3 activity in 105 cells after 3 days in culture
without (0 µmol/L) or with (1 µmol/L) STI571. Results represent the mean 6 SD of
triplicate cultures.
Figure 3. Cell proliferation of LAMA84, AR230, K562, and KCL22 sensitive (s)
and resistant (r) clones under the effect of various concentrations of STI571, as
assessed by MTS uptake. Results are expressed as the mean OD490 of quadrupli-
cate cultures, which is directly proportional to the number of viable cells.
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respectively, on immunoblot with an anti-Abl antibody (Figure
5B). Because neitherAR230 nor LAMA84 contains a normalABL
gene, we were able to conﬁrm the overexpression of Bcr-Abl in
their resistant clones by ﬂuorocytometry of permeabilized cells
stained with an anti-Abl mAb (Figure 6). After removal of STI571
from the culture, the degree of Bcr-Abl overexpression was
signiﬁcantly lower in both AR230-r and LAMA84-r; it was
reduced to 1.5 and 5.6 times the levels found in AR230-s and
LAMA84-s, respectively (Figure 5B). A similar 2.5-fold reduction
in the BCR-ABL mRNA level was observed after LAMA84-r cells
were withdrawn from STI571 for 7 days (data not shown).
Because the BCR-ABL gene is under control of the BCR
promoter,17,18 we also analyzed the fusion protein expression using
an anti-Bcr antibody to check the level of the normal Bcr protein.
Figure 5C conﬁrms that Bcr-Abl is overexpressed in LAMA84-r
cells, but there is no signiﬁcant change in the level of Bcr in this
clone. In contrast,AR230-r cells express very small amounts of Bcr
protein compared with the parentalAR230-s.
In the other 2 cell lines, K562-r and KCL22-r, no up-regulation
of BCR-ABL mRNA or protein expression was observed. The
overall results show that resistance to STI571 is mediated by
Bcr-Abl overexpression in some, but not all, cell lines and that this
overexpression can be reversed at least partially by withdrawal of
the tyrosine kinase inhibitor from the culture.
Some resistant cell lines have ampliﬁcation
of the BCR-ABL gene
To investigate the cause of Bcr-Abl overexpression in some of the
resistant cell lines, we performed ﬂuorescence in situ hybridization
(FISH) analysis of interphase nuclei with probes against the BCR
and the ABL genes. Similar to what has been described for K562,19
the parentalAR230 and LAMA84 cell lines had multiple copies of
the BCR-ABL gene (Table 1). However, resistant clones from both
lines exhibited signiﬁcant increases in the number of BCR-ABL
copies (Figure 7). For AR230-r there was an approximately 3-fold
increase, whereas for LAMA84-r there was a nearly 6-fold
ampliﬁcation, with as many as 19 to 28 fusion signals discernible
per cell (Table 1). In the resistant cell lines, the hybrid signals
tended to cluster in individual regions of the nucleus (Figure 7). No
signiﬁcant change in the number of fusion genes was observed in
Figure 4. BCR-ABL expression in Baf/BCR-ABL clones. Western blots probed
with anti-Abl (upper part of the ﬁlters) and anti-actin (lower part of the ﬁlters)
antibodies. (A) Lane 1: Baf/BCR-ABL-s. Lanes 2-5: 4 Baf/BCR-ABL clones resistant
to 1 µmol/L STI571. Lanes 6, 7: 2 Baf/BCR-ABL clones resistant to 3 µmol/L STI571.
Note that one tenth the protein was loaded onto the latter 2 lanes to enable resolution
of the 210-kd Bcr-Abl band without saturation of the image. Densitometric Bcr-Abl/
actin ratio for each sample showed an average 7-fold Bcr-Abl overexpression in the
clones resistant to 1 µmol/L STI571 and 34-fold in those resistant to 3 µmol/L in
comparison with the level of expression in the sensitive parental line. (B) Modulation
of Bcr-Abl expression in Baf/BCR-ABL cells grown for 3 days in the presence (1)o r
absence (2) of IL-3, STI571, or both. The P210/actin ratios indicate that the removal
of STI571 leads to a weak reduction in the level of Bcr-Abl protein and that the effect is
signiﬁcantly enhanced by the addition of IL-3. These results were reproduced in 4
identical experiments. (C) BCR-ABL mRNA levels in Baf/BCR-ABL-r1 cells after 3-
and 7-day withdrawal of STI571 from the culture.
Figure 5. BCR-ABL expression in AR230 and LAMA84. (A) Northern blot analysis
of BCR-ABL (with an ABL probe) and b-actin (loading control) mRNAin the sensitive
and resistant cells. Densitometric analysis of the BCR-ABL/actin ratio showed a 1.6-
and a 5.5-fold increase in AR230-r and LAMA84-r, respectively, compared with their
sensitive parental lines. (B) Western blot probed with anti-Abl (upper part of the ﬁlter)
and anti-actin (lower part of the ﬁlter) antibodies. Bcr-Abl overexpression in relation to
the sensitive counterparts was estimated by densitometry of the Bcr-Abl/actin ratio as
6-and 12-fold in AR230-r and LAMA84-r, respectively; these values were reduced to
1.5- and 5.6-fold, respectively, 7 days after withdrawal of STI571 from the culture. (C)
Western blot probed with anti-Bcr (upper part of the ﬁlter) and anti-actin (lower part of
the ﬁlter) antibodies. CML-T1, which does not express normal Bcr protein, and
KCL22, which does, were used as negative and positive controls, respectively.
LAMA84-r overexpresses both Bcr (160 kd) and Bcr-Abl (210 kd) compared
withA84-s. LAMA84-r* corresponds to the subline maintained in culture without
STI571 for 1 week, in which reductions in Bcr-Abl and Bcr expression can be
observed.AR230-r cells express a lower level of Bcr protein thanAR230-s in spite of
the Bcr-Abl overexpression.
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from the culture media (Table 1).
Attempts at FISH analysis in the Baf/BCR-ABL–derived cell
lines using different sources of genomic BCR and ABL probes were
unsuccessful. Therefore, we investigated the possibility of gene
ampliﬁcation in these lines by Southern hybridization with cDNA
probes spanning sequences present in the pGD210 provirus3 used
for the transduction of BCR-ABL into Ba/F3. On average, 5.7-fold
stronger signals for BCR and ABL sequences were observed in
Baf/BCR-ABL-r clones resistant to 1 µmol/L and 3 µmol/L than in
Baf/BCR-ABL-s cells in duplicate experiments (data not shown).
Some resistant cell lines require higher STI571 concentrations
for the inhibition of Bcr-Abl phosphorylation
To investigate whether resistance to STI571 resulted from a lack or
a reduction in inhibition of the Bcr-Abl kinase activity, we analyzed
the effect of the compound on the phosphorylation pattern of the
various cell lines. Sensitive and resistant clones were washed with
RF-10, incubated in graded concentrations of STI571 for 2 hours,
and processed for Western blots, which were probed with an
anti-phosphotyrosine antibody (Figure 8). Phosphorylation of
various proteins decreased in a dose-dependent manner in the
sensitive and resistant clones. However, the doses of STI571
necessary to inhibit overall tyrosine phosphorylation were higher
for K562-r (Figure 8A), LAMA84-r, andAR230-r (not shown) than
for the respective parental clones. Densitometric quantiﬁcation of
the phosphorylated p210BCR-ABL band was used to calculate the IC50,
that is, the dose of STI571 that inhibits 50% of the phosphorylation
of Bcr-Abl itself (Table 2). We found that the IC50 for the human
CMLcell lines was approximately 0.5 µmol/Lbut that a dose twice
Figure 6. Flow cytometric histograms of AR230 and LAMA84 sensitive (S) and
resistant (R) clones stained with an anti-Abl mAb. The arrow indicates the proﬁle
of a BCR-ABL–negative cell line (HL60) stained with the same antibody. Relative
ﬂuorescence values are shown on the x axis.
Figure 7. FISH analysis of AR230 and LAMA84 sensitive and resistant clones,
with probes for the ABL (red signal) and the BCR (green signal) genes.
BCR-ABL is identiﬁed as a red–green or yellow fused signal.
Figure 8. Phosphotyrosine immunoblots and control staining of the same blots
(after strip-washes) with anti-Abl or anti-actin antibodies. (A) K562-sensitive and
-resistant clones after a 2-hour incubation with graded concentrations of STI751. (B)
K562-, KCL22-, AR230-, and LAMA84-resistant sublines incubated for 8 days in the
presence (1) or absence (2) of 1 µmol/L STI571. The arrows indicate protein bands
of approximately 110 and 55 to 58 kd, which become or remain hyperphosphorylated
in K562-r and KCL22-r, respectively.
Table 1. Number of BCR-ABL fusion signals as detected by FISH
Cell line Sensitive Resistant 1STI571 Resistant 2STI571
AR230 2.9 6 0.6 9.6 6 1.8 8.6 6 1.5
(2-4) (7-12) (7-12)
n 5 15 n 5 15 n 5 15
LAMA84 4.3 6 0.7 23.8 6 2.5 23.1 6 2.9
(3-5) (19-28) (18-29)
n 5 15 n 5 30 n 5 30
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murine cell line transfected with BCR-ABL. In the latter, as well as
in KCL22, no difference was observed in the IC50 between the
sensitive and the resistant clones. In contrast, LAMA84-r and
AR230-r showed a 2.5-fold increase in the STI571 IC50, and this
index was increased 4-fold in K562-r.
We next analyzed the tyrosine phosphorylation proﬁle of
proteins in the resistant clones after 8 days in culture with and
without 1 µmol/L STI571.As expected, the phosphotyrosine content of
the 3 resistant cell lines that required higher STI571 concentrations for
effective Bcr-Abl inhibition remained largely unchanged (Figure
8B). In K562-r however, an approximately 110-kd protein became
hyperphosphorylated in the presence of 1 µmol/L STI571, whereas
phosphorylation of a slightly smaller band at approximately 102 kd
was exceptionally inhibited under these conditions. As a further
conﬁrmation of the IC50 measurements, the phosphotyrosine con-
tent of most proteins in KCL22-r was signiﬁcantly reduced in the
presence of the compound, but a group at approximately 55 to 58
kd remained strongly phosphorylated (Figure 8B). Thus, the
possibility that other cellular kinases unresponsive to STI571 activate a
part of the Bcr-Abl pathway cannot be excluded for K562-r and
KCL22-r. Altogether, the results suggest that resistance to STI571
in AR230-r, LAMA84-r, and K562-r at least in part results from a
reduced inhibition of Bcr-Abl kinase activity by concentrations of
the compound effective in their sensitive parental lines.
Expression and function of the Pgp multidrug
resistance protein
Inappropriate expression of the MDR-1 gene that codes for the Pgp
glycoprotein has been frequently implicated in the mechanism of
resistance to different drugs used in chemotherapy. Overexpression
of Pgp can functionally modify the uptake of several drugs.20 We
studied the pattern of Pgp expression by ﬂourocytometry in the 3
resistant clones that showed increased requirements for STI571 for
Bcr-Abl kinase inhibition.AR230-r and K562-r showed negligible,
baseline levels of Pgp that overlapped the proﬁles of their sensitive
counterparts.Incontrast,LAMA84-rexhibitedasigniﬁcantoverex-
pression of Pgp: more than 50% of the resistant cells showed a
strong reaction to the anti-Pgp antibody compared with only 2% of
the LAMA84-s parental line (Figure 9A). The experiments that
followed aimed at establishing the functional relevance of this
overexpression. LAMA84-r cells were incubated with verapamil, a
known inhibitor of Pgp, and were assessed for viability on
exposure to different concentrations of STI571. Although no
signiﬁcant change in their usual resistance to 1 µmol/LSTI571 was
elicited, a clear enhancement of sensitivity to the higher 2 µmol/L
dose of the compound was observed when verapamil was added to
the culture (Figure 9B). Because the STI571 IC50 for LAMA84-r is
higher than that for LAMA84-s, we also established the IC50 for
LAMA84-r after incubation with verapamil to investigate whether
such treatment could modify and decrease the doses of STI571
necessary to inhibit Bcr-Abl tyrosine kinase (Figure 9C). In fact,
the IC50 for LAMA84-r cells, which is 1 µmol/L (Table 2), was
reversed to 0.4 µmol/L after the addition of verapamil, the same
value found for LAMA84-s. No change in the IC50 for the latter
was detected on treatment with verapamil. We conclude that
LAMA84-r cells overexpress Pgp, a phenomenon that may impair
the uptake of STI571 by this resistant subline.
Sequencing of the Abl kinase domain
For STI571-resistant cells that did not overexpress BCR-ABL but
that did have higher IC50 values than their sensitive counterparts,
such as K562-r, we asked whether resistance to the compound
could be caused by a modiﬁcation in theATPbinding site of theAbl
kinase domain, thought to be the target of STI571. To address this
question, we sequenced the entire kinase domain of K562-sensitive
and -resistant cells and ofAR230-sensitive and -resistant clones (as
controls) and compared these to the published sequences.21,22 No
mutation was found in an 856-bp fragment, including the Abl
kinase domain, in any of the cell lines.
Discussion
STI571 can be regarded as the ﬁrst member of a new family of
drugs termed signal transduction inhibitors. It was designed based
Figure 9. Expression and function of the Pgp MDR-1 gene product in LAMA84.
(A) Flow cytometric analysis of Pgp expression in LAMA84-r and LAMA84-s clones.
Note that the histogram for the latter overlaps that of cells stained with the isotypic
control. (B) Effect of verapamil on the viability of LAMA84-r cells incubated with 1
µmol/L(left panel) or 2 µmol/L(right panel) STI571. (C) Effect of verapamil on the IC50
of LAMA84 cells. Upper panels show Western blots of LAMA84-s, LAMA84-r, and
LAMA84-r treated with verapamil for 2 hours, probed with an anti-phosphotyrosine
(pTyr) and with anti-Abl (Bcr-Abl band shown) or anti-actin antibodies. Lower panel
illustrates the decrease in the IC50 for Bcr-Abl phosphorylation in LAMA84-r cells
exposed to verapamil (VP), as calculated by densitometric analysis of the ratio
pTyr-Bcr-Abl/Bcr-Abl or pTyr-Bcr-Abl/actin. We have ascertained that verapamil does
not modify the IC50 in LAMA84-s cells (data not shown).
Table 2. IC50 values for inhibition of Bcr-Abl phosphorylation by STI571
Cell lines
IC50 (µM STI571)
Sensitive sublines Resistant sublines
Baf/BCR-ABL 1 1
LAMA84 0.4 1
AR230 0.4 1
K562 0.5 2
KCL22 0.4 0.4
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displays speciﬁcity at the submicromolar level for the Abl, PDGF,
and Kit receptor kinases and selectively kills BCR-ABL–
expressing cells.7,8,23 Nevertheless, we observed previously that
rare Ph-positive cell lines are unaffected by concentrations of
STI571 that suppress the proliferation of most CML cell lines and
that a few primary BCR-ABL positive progenitors from peripheral
blood or bone marrow are resistant to the compound.9 Relapse from
tumor growth in mice injected with BCR-ABL–positive human cell
lines and treated with STI571 has also been reported,24 suggesting
the development of resistance in vivo. To study this phenomenon,
we generated sublines with differential sensitivity to STI571 from
BCR-ABL positives cell lines and investigated the possible mecha-
nisms of their resistance to this compound.
The ﬁrst remarkable observation from this exercise was the
overall difficulty in generating resistant clones from the STI571-
sensitive cell lines. This was particularly pronounced among the
human Ph-positive lines.Although all 8 STI571-sensitive cell lines
were clonogenic in methylcellulose, none was able to generate
colonies in the presence of the compound. Even when subjected to
a gradual exposure to STI571 in liquid culture, no cell survival was
observed in 4 of the 8 lines at concentrations above 0.2 µmol/L.The
inability to isolate resistant clones from some cell lines did not
correlate with obvious cellular and molecular characteristics, such
as blast crisis lineage, p53 status, FAS receptor expression, or
structure (junction) of the BCR-ABL mRNA (data not shown). In
the 4 cell lines from which clones of STI571-resistant cells were
obtained, these represented rare survivors from massive cell killing
at each step of dose increase, suggesting that they arose in response
to selective pressure of the inhibitor. These results emphasize the
speciﬁcity and high efficacy of this drug for the control of
proliferation of BCR-ABL–positive cells and show that develop-
ment of resistance among these cells is, at least in vitro, a rare
phenomenon.
Nevertheless, occasional cells do escape the pro-apoptotic
effect of STI571 compound9 and are able to establish a subline of
cells that can grow continuously in the presence of pharmacologic
doses24 of the compound. It is interesting to observe that although
these resistant sublines are not killed by the tyrosine kinase
inhibitor, their proliferation is slowed in comparison with the
parental cultures (Figure 2C), suggesting that a delaying effect over
the cell cycle is still elicited by the drug.This pattern of growth was
also described in cell lines resistant to other drugs, such as cytosine
arabinoside, colchicine, vinca alkaloids, epidophyllotoxins, anthra-
cycline, and actinomycin D, with cross-resistance between them
characterizing the multidrug resistance phenotype (reviewed
inArceci25).
The mechanisms by which a rare subpopulation of cells within
susceptible BCR-ABL–positive lines becomes resistant to STI571
differ between the different lines. The most common, detected in
the BCR-ABL–transfected murine Ba/F3 cells and in the human
LAMA84 and AR230 CML cell lines, is overexpression of the
Bcr-Abl protein. By increasing the amount of oncoprotein requir-
ing inhibition of its kinase activity, the cell can survive concentra-
tions of STI571, which then become suboptimal for competing out
all the ATP binding. This is most clearly illustrated by the various
Baf/BCR-ABL-r clones in which the degree of Bcr-Abl overexpres-
sion was directly correlated with the concentration of STI571 to
which the individual clone was resistant (Figure 4). Similar
behavior in the development of resistance to other chemotherapeu-
tic agents has been described in cases of Pgp overproduction.26,27
The molecular basis for Bcr-Abl overexpression in all 3
resistant lines is, at least in part, a signiﬁcant ampliﬁcation of the
BCR-ABL gene itself. The precedent for gene ampliﬁcation as the
underlying cause of drug resistance has been extensively docu-
mented for the MDR and the multidrug-resistance related protein
genes.28,29 In our study, however, this ﬁnding was somewhat
surprising in view of the fact that the degree of overexpression
could be relatively rapidly modulated in the 3 cell lines by
withdrawal of the inhibitor and by addition of IL-3 in the case of
Baf/BCR-ABL-r.As expected this reduction in the level of Bcr-Abl
overexpression was not accompanied by a similar decrease in the
multiplicity of BCR-ABL genes. It thus appears that mechanisms
responsible for controlling transcription and translation from the
ampliﬁed genes are also in operation in each resistant line. If such a
control were effected at the level of the BCR-ABL gene promoter, it
might be expected that expression of the normal BCR mRNA and
protein would be similarly increased in resistant clones. This was
not the case for LAMA84-r cells, and, in fact, the opposite
phenotype—that is, a decrease in normal Bcr expression—was
observed in AR230-r. Although the molecular basis for this
phenomenon is unknown, the reduced levels of Bcr protein could
contribute to the resistance ofAR230-r cells to STI571 because Bcr
has been described as a negative regulator of Bcr-Abl.30
An alternative mechanism for the modulation of Bcr-Abl
expression in the resistant lines would be a decrease in Bcr-Abl
protein degradation through the inhibition of a cellular protease.
This is, in fact, a frequent phenomenon in the regulation of
apoptotic processes in which a family of inhibitors of apoptosis
proteins can modulate cell death by the abrogation of caspase
activity.31 However, an increase rather than a reduction in Bcr-Abl
degradation products was detected in Baf/BCR-ABL-r cells (Figure
3B), suggesting that this would be an unlikely explanation for the
reversible Bcr-Abl overexpression in this cell line.
In 2 of the resistant human cell lines, K562-r and KCL22-r, the
levels of Bcr-Abl protein were comparable to those in their
sensitive counterparts, indicating that other mechanisms underlie
the resistance of these lines to STI571. The possibility that these
cells had developed increased requirements for the compound for
effective tyrosine kinase inhibition proved to be the case for
K562-r, as well as for LAMA84-r and AR230-r, but not for
KCL22-r, as shown by their respective STI IC50 for the inhibition
of Bcr-Abl phosphorylation (Table 2). This biologic behavior has
also been described in the development of resistance to other
agents, such as anthracycline and vinca alkaloids in leukemic cells,
and is usually attributed to a decrease in the cellular uptake of the
drug.32,33 The most extensively studied mediator of this phenom-
enon is the Pgp protein encoded by the MDR-1 gene, which affects
the uptake of a soluble compound by ‘‘pumping out’’ the drug
through the plasma membrane.20,25 Measurement of Pgp expression
in the 3 STI571-resistant cell lines with high IC50 showed that 1 of
them, LAMA84-r, did indeed overexpress Pgp, in comparison with
the LAMA84-sensitive line. Moreover, inhibition of Pgp with
verapamil, a potent blocker of the pump, led to an improved uptake
of STI571 in LAMA84-r, as shown by the reduction of its IC50.I ti s
important to note, though, that the inhibition of Pgp also resulted in
enhancement in the sensitivity of LAMA84-r to higher doses of
STI571, but it was insufficient to overcome their resistance to the 1
µmol/L concentration in which they normally survive, probably
because this cell line carries a second, independent mechanism of
resistance (Bcr-Abl overexpression), which on its own is able to
sustain the basic resistant phenotype.
The reasons for the increased requirement for STI571 in K562-r
andAR230-r were not apparent. Mutations in the Bcr-Abl tyrosine
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binding of the compound to theATPbinding site, were not found in
either cell line. It is possible, however, that other proteins such as
the recently described multidrug-resistance related protein34 may
be involved in reducing the STI571 uptake in these cells.
The resistance of KCL22 is the most intriguing of all because
none of the obvious mechanisms investigated in this study were
present in this line. It should be noted that the original, parental
KCL22 is the only line among 12 CML cell lines tested in our
laboratory9 (and unpublished observations) that is largely resistant
to STI571. Even the few sensitive clones that could be isolated
from this line showed some degree of resistance to the inhibitor,
represented by a longer survival in 1 µmol/L STI571 than that
exhibited by the other sensitive cell lines (Figure 2A). The fact that
KCL22 can resist the apoptotic effect of STI571 without increasing
the level of Bcr-Abl expression and still undergoing effective
Bcr-Abl tyrosine kinase inhibition suggests that this cell line has
evolved an alternative abnormality to circumvent the Bcr-Abl–
dependent susceptibility to STI571.The nature of such abnormality
cannot be inferred from this study, but it may be related to a group
of 55- to 58-kd proteins that remain constitutively hyperphosphory-
lated when tyrosine phosphorylation of all Bcr-Abl–dependent
proteins is well inhibited (Figure 8B). Investigations aiming at
identifying this putative genetic event are in progress.
In conclusion, our data show that resistance to STI571 among
BCR-ABL–positive cells is a rare phenomenon and may develop
through multiple mechanisms, such as Bcr-Abl overexpression,
reduction in the uptake of the compound by Pgp overexpression, or
possibly by excessive degradation. We cannot exclude that the
acquisition of compensatory mutations in genes other than BCR-
ABL also plays a part. It is possible that the same or similar
mechanisms operate in a few primary CMLprogenitors that escape
the in vitro antiproliferative effect of the compound.9 Thus
ampliﬁcation of the BCR-ABL gene, usually detected as the
emergence of extra Ph-chromosomes, is a frequent event in blast
crisis of CML,35 when the transformed leukemic clone becomes
refractory to virtually all chemotherapeutic agents. Similarly, an
increase in BCR-ABL mRNA expression has been described in 1
study as a marker of disease progression,36 though the magnitude of
this overexpression has been questioned.37 It has also been reported
that during the evolution of the disease to blast crisis, patients with
CMLmaybecomeresistanttotreatmentbecauseofPgpoverexpres-
sion.38 Because STI571 is being tested in clinical trials for its
therapeutic beneﬁts in CML,11 it will be important to determine
whether CML stem cells are able to develop in vivo these reactive
strategies to survive the effects of this potent drug.
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